INTERVIEW

Me Pharma Sees Opportunities in Low-Cost Strategy, Could Carve Out New Biz Models: President

August 14, 2017

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

While the Japanese generic market continues to grow on the back of the government’s push for its 80% share target, relentless pricing pressure and fierce competition are casting a shadow on the future of the industry. Me Pharma, a subsidiary…

To read the full story

Me Pharma Eyes Production of 1 Billion Tablets in FY2021, Sales Buoyed by Low Prices
March 12, 2021
Meiji to Strengthen Contract Manufacturing, Aims to Produce 3 Billion Tablets Annually for Japan Market
October 10, 2019
Meiji Seika Pharma Forms Generic Subsidiary
May 10, 2017

INTERVIEW

Interview: Mathematician Changing the Future of Drug Discovery (FRONTEO CTO)
March 25, 2025
From Treatment to Prevention, Top Expert on AD Research, Aducanumab and Its Implications - 2
February 8, 2021
Alzheimer’s Treatment at Crossroads? Top Expert on AD Research, Aducanumab and Its Implications - 1
February 2, 2021
Improper Materials Apparently Decreased after Promotion Guidelines Introduced: Pharmacist
February 10, 2020
“Excessive Self-Restraint” of Promotion Activities by Drug Makers Hindering Drugs’ Lifecycle Management: Physician
January 28, 2020

Chuikyo Debate on FY2026 Drug Pricing Reform

Gist of FY2026 Drug Pricing Reform Outline

The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…

COMMENTARY

Wave of “World Firsts” Looms as 47 New Drug Candidates Line Up for 2026

By Shinya Sato

As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…